Basic Information


GTO ID GTC3448
Trial ID NCT05868382
Disease Influenza
TherapymRNA vaccine
Treatment mRNA-1010;mRNA-1010.4;mRNA-1010.6
PhasePhase2
Recruitment statusCompleted
TitleA Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
Year2023
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-CRID-004
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-1010
Administration route intramuscular injection
Dosage mRNA-1010, single dose, on Day 1
Age Adult
Cohort2: mRNA-1010.4
Administration route intramuscular injection
Dosage mRNA-1010.4, single dose, on Day 1
Age Adult
Cohort3: mRNA-1010.6
Administration route intramuscular injection
Dosage mRNA-1010.6, single dose, on Day 1
Age Adult

Relationship Graph

Overview of Knowledge Graph